- Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
- Alkermes plc Reports First Quarter 2024 Financial Results
- Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
- Alkermes to Report First Quarter Financial Results on May 1, 2024
- Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
- Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
- Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
- Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
More ▼
Key statistics
On Friday, Alkermes Plc (ALKS:NSQ) closed at 24.05, 9.27% above its 52-week low of 22.01, set on Oct 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.35 |
---|---|
High | 24.46 |
Low | 24.04 |
Bid | 24.00 |
Offer | 26.99 |
Previous close | 24.26 |
Average volume | 1.65m |
---|---|
Shares outstanding | 169.22m |
Free float | 167.11m |
P/E (TTM) | 6.93 |
Market cap | 4.11bn USD |
EPS (TTM) | 3.50 USD |
Data delayed at least 15 minutes, as of May 10 2024 21:00 BST.
More ▼